Phase I trial of vindesine in patients with advanced cancer

Cancer Treat Rep. 1978 Sep;62(9):1333-6.

Abstract

A phase I evaluation of vindesine was carried out in 69 adult patient with advanced malignancies. Two escalating dose schedules were explored: (a) a single dose every 7--14 days, and (b) daily injections X 5--10 days as tolerated. The main toxic effects were myelosuppression, alopecia, paresthesia, asthenia, myalgia, and hyporeflexia. Antitumor activity was seen during this phase I study in patients with leukemia, lymphoma, and testicular neoplasms. Disease oriented phase II trials of 3--4 mg/m2 every 7--14 days or 1.3--2.0 mg/m2/day X 5--7 days every 3 weeks would be appropriate.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Humans
  • Leukemia / drug therapy
  • Lymphoma / drug therapy
  • Male
  • Neoplasms / drug therapy*
  • Testicular Neoplasms / drug therapy
  • Vinca Alkaloids / administration & dosage
  • Vinca Alkaloids / therapeutic use*

Substances

  • Vinca Alkaloids